Patent: 6,664,107
✉ Email this page to a colleague
Summary for Patent: 6,664,107
Title: | CD45 disrupted nucleic acid |
Abstract: | A mammal lacking expression of particular CD45 isoform in certain cells of the immune system is provided. The mammal may optionally contain a transgene encoding the CD45RO isoform. Also provided are methods of using these mammals. |
Inventor(s): | Mak; Tak Wah (Toronto, CA), Kishihara; Kenji (Fukuoka, JP) |
Assignee: | Ontario Cancer Institute, University Health Network (Toronto, CA) |
Application Number: | 08/191,225 |
Patent Claims: | see list of patent claims |
Details for Patent 6,664,107
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2020-12-16 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2020-12-16 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2020-12-16 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |